Focal segmental glomerular sclerosis in kidney allograft recipients: An evidence-based approach

Rahul Koushik, Arthur J Matas

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Focal segmental glomerular sclerosis (FSGS) causes kidney failure in 2.5% of all end-stage kidney disease patients. FSGS recurs in 20% to 30% of kidney allografts. In a third of kidney recipients with recurrent FSGS, graft loss is attributed to recurrent disease. Complicating the understanding of recurrent FSGS are the facts that (a) many patients with end-stage kidney disease do not undergo a kidney biopsy before transplant and (b) "de novo" FSGS is not uncommon after transplant, occurring in up to 30% of allografts. This review aims to clarify the definitions of recurrent FSGS and to identify risk factors for treatable recurrent FSGS. The pathophysiology of FSGS and therapeutic strategies from clinical trials are discussed.

Original languageEnglish (US)
Pages (from-to)78-87
Number of pages10
JournalTransplantation Reviews
Volume19
Issue number2
DOIs
StatePublished - Apr 1 2005

Fingerprint Dive into the research topics of 'Focal segmental glomerular sclerosis in kidney allograft recipients: An evidence-based approach'. Together they form a unique fingerprint.

Cite this